A major milestone in the development of a new malaria vaccine has been reached with today’s publication of results from a phase IIb trial showing that the vaccine is, as expected, highly effective at preventing infection. The global health community has been working towards a malaria vaccine for over 30 years and this is the first time a vaccine has achieved efficacy at this level.
This represents an important step forward in eliminating this disease from humankind and allowing everyone to lead a more healthy life. The results from this study are particularly gratifying as they demonstrate the feasibility of this vaccine candidate entering phase III clinical development, which will enable it to reach patients faster and at a higher dose than currently available drugs.
Last year, we reported results from a Phase IIb trial conducted at the Clinical Research Unit of Nanoro (CRUN) / Institut de Recherche en Sciences de la Santé (IRSS) in Burkina Faso.
We conducted a study of 450 participants aged 5 to 17 months, recruited from the catchment area of Nanoro, which includes 24 villages with a total population of 65,000 people.
A single-blinded, dose–finding, phase 2a clinical trial conducted in Ghana and Malawi over the spring and summer of 2019 revealed Matrix-M to be 20 times more effective than a rabies vaccine at eliciting an immune response to the malaria protein R2.
In a study funded by RIA2016V-1649-MMVC -the second phase of the vaccine evaluation trial was finished. There is a 77% chance to reduce the HPV Virus infection in women who received adjuvant and booster vaccine at the same day.